A Federal Vaccine Compensation Program Is Buckling Under Its Own Backlog

Why It Matters

A new Congressional Research Service report published May 4 puts a spotlight on a quiet but deepening crisis inside the federal government's vaccine injury compensation system, one with direct implications for the Trump administration's health policy agenda and for families waiting years to resolve their claims.

The National Vaccine Injury Compensation Program was built on a straightforward bargain: vaccine manufacturers get shielded from most civil lawsuits, and people who believe they were harmed by a covered vaccine get a dedicated, no-fault compensation pathway. But that pathway has a statutory clock attached to it, and the clock is being routinely ignored.

Federal law requires that VICP petitions be adjudicated within 240 days of filing. According to the CRS report, the average case now takes two to three years to resolve. The body responsible for adjudicating every vaccine injury claim in the country, the Office of Special Masters, has just eight special masters handling the entire national caseload.

The result is a structural contradiction at the heart of federal vaccine policy: the program designed to keep vaccine injury disputes out of civil courts is, through its own delays, pushing claimants back toward the very litigation it was meant to replace.

The Big Picture

Congress created the VICP through the National Childhood Vaccine Injury Act of 1986 as a no-fault alternative to traditional tort litigation. Before suing a vaccine manufacturer or administrator in civil court, claimants must generally exhaust their remedies through the VICP petition process first.

The 240-day adjudication requirement was written into the statute as a safeguard. If the Office of Special Masters fails to issue an entitlement decision within that window, a petitioner may voluntarily dismiss the petition and proceed to civil court. In theory, this provision protects claimants from being trapped indefinitely in an administrative process. In practice, given that cases routinely stretch two to three years, the provision has become the central fault line in active federal litigation.

The CRS report focuses significant attention on the ongoing Gardasil multidistrict litigation in the U.S. District Court for the Western District of North Carolina, involving Merck's HPV vaccine. In that case, Merck argued that plaintiffs' civil claims should be dismissed because they had not properly exhausted their VICP remedies. The district court agreed and dismissed the claims. The petitioners appealed to the Fourth Circuit, arguing that a special master's timeliness ruling carries no force in a civil tort suit and that their civil action should be treated as a fresh proceeding.

The Fourth Circuit's eventual ruling could redefine what "exhaustion" of VICP remedies actually means, and by extension, determine whether claimants who were simply caught in the program's backlog can access the civil court system at all.

Political Stakes

For the Trump administration, the report arrives at a complicated moment on multiple fronts.

HHS Restructuring and Staffing. The administration's effort to reduce the size of the Department of Health and Human Services, driven in part by the DOGE initiative, has already produced significant staff reductions across the department. The CRS report underscores that the Office of Special Masters is already operating with minimal capacity. Eight special masters handling the full national vaccine injury claim caseload is not a system with slack. Any further reduction in administrative or legal staffing at HHS or at the Health Resources and Services Administration, which administers the VICP, would deepen an existing backlog and increase the likelihood that more petitioners are pushed toward civil litigation, an outcome Congress specifically designed the program to prevent.

RFK Jr. and the VICP's Future. HHS Secretary Robert F. Kennedy Jr. has been a long-standing and vocal critic of federal vaccine programs. The tension the CRS report identifies, between VICP's mandatory pre-suit exhaustion requirements and claimants' access to civil courts, sits directly in the middle of a broader policy debate about whether the 1986 Act's liability framework should be revisited. Any administrative or legislative move to weaken the exhaustion requirement or expand civil litigation pathways would carry significant consequences for vaccine manufacturers and for the compensation fund itself.

The Gardasil Litigation. The active Fourth Circuit appeal puts the administration in an awkward position. The administration has been broadly skeptical of vaccine manufacturers, but the VICP's liability shield for manufacturers is the structural foundation of the 1986 Act's bargain. If courts begin to erode that shield by allowing civil suits to proceed without proper VICP exhaustion, the downstream effects on the vaccine market and on public health infrastructure could be substantial. Congressional action may ultimately be required to clarify the statute.

Vaccine Schedule Changes. A companion CRS report, LSB11427, published the same day, examines the litigation implications of changes to the CDC's childhood vaccine schedule. If vaccines are removed from the schedule under the current administration, those vaccines would lose VICP coverage entirely, eliminating the no-fault compensation pathway for any injuries associated with them and raising serious equity concerns for affected families.

The Bottom Line

The VICP petition process is failing to meet its own statutory timeline, and that failure is now generating federal litigation that could fundamentally reshape the program's legal architecture. The 240-day adjudication requirement was designed as a backstop, not a routine exit ramp, but chronic undercapacity in the Office of Special Masters has made it the latter.

For Congress, the report is a signal that the program requires either additional resources or statutory clarification, or both. For the administration, the stakes are harder to navigate: decisions about HHS staffing levels, the CDC vaccine schedule, and the posture toward vaccine manufacturers all converge directly on the legal framework the CRS is now flagging as under strain.

The Fourth Circuit's ruling in the Gardasil case will be the first major test of how much pressure that framework can absorb.

Access the Legis1 platform for comprehensive political news, data, and insights.